Metropolis Healthcare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Metropolis Healthcare Ltd filed with BSE on 19 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Metropolis Healthcare reported Q4 FY26 group revenue of Rs 425 crore, up 23% year-on-year, with an EBITDA margin of 25.4%, while full year FY26 revenue reached Rs 1,646 crore, up 23.6%. Organic revenue growth for the year was 13.7%, ahead of the company's stated 12-13% guidance, with organic EBITDA margin expanding to 25.9%. Management also discussed the integration of Core Diagnostics, which reached a high-single-digit EBITDA margin in Q4, and outlined plans for network expansion including mini hubs and additional collection centers over the next three years.
Numbers mentioned
Group revenue: INR 425 crores (Q4 FY26)
p. 7
“For quarter 4 '26, MHL Group revenue stood at INR 425 crores, reflecting a year-on-year growth of 23% with EBITDA margin of 25.4%”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
Group revenue: INR 1,646 crores (FY26)
p. 7
“For the full year, revenue stood at INR 1,646 crores, growing 23.6% year-on-year with an EBITDA margin of 24.4%”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
Organic revenue growth: 14.7% (Q4 FY26)
p. 7
“On an organic basis, revenue grew by 14.7% in quarter 4, driven largely by patient volume growth of 9.3% and realization improvement of around 5%”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
Organic revenue growth: 13.7% (FY26)
p. 7
“For the full year, organic revenue growth stood at 13.7%”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
Organic EBITDA margin: 27.2% (Q4 FY26)
p. 8
“Organic EBITDA margin for the quarter stood at 27.2% compared to 18.5% in the same period last year, while the full year EBITDA margin came in at 25.9%”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
Organic revenue: INR 392 crores (Q4 FY26)
p. 9
“Quarter 4 FY26 revenue stood at INR 392 crores, growing 14.7% year-on-year, supported by 9% growth in both patient and test volume”
Sameer Patel, page 9 of the filed PDF · View the filing
Organic revenue: INR 1,510 crores (FY26)
p. 9
“Full year FY26 revenue stood at INR 1,510 crores, reflecting 13.7% year-on-year growth with patient volume growth at 7.5% and test volume growth at 8%”
Sameer Patel, page 9 of the filed PDF · View the filing
Organic EBITDA: INR 392 crores, margin 25.9% (FY26)
p. 9
“Full-year FY26 EBITDA stood at INR 392 crores with a margin of 25.9%, reflecting 29% year-on-year growth”
Sameer Patel, page 9 of the filed PDF · View the filing
Organic PAT: INR 194 crores, margin 12.8% (FY26)
p. 9
“Full-year FY26 PAT stood at INR 194 crores, with a margin of 12.8% and 33% year-on-year growth”
Sameer Patel, page 9 of the filed PDF · View the filing
Group EBITDA: INR 401 crores, margin 24.4% (FY26)
p. 10
“Full year FY26 EBITDA stood at INR 401 crores with a margin of 24.4%, reflecting 32% growth year-on-year”
Sameer Patel, page 10 of the filed PDF · View the filing
Group PAT: INR 191 crores, margin 11.6% (FY26)
p. 10
“Full-year FY26 PAT stood at INR 191 crores with a margin of 11.6%, grew by 31% year-on-year”
Sameer Patel, page 10 of the filed PDF · View the filing
Capex: INR 65 crores (FY26)
p. 10
“We have incurred a capex the capex stood at INR 65 crores”
Sameer Patel, page 10 of the filed PDF · View the filing
Centers added: 490 centers (FY26)
p. 8
“During the year, we added 490 centers, taking our total network to over 5,000 collection centers across more than 750 towns and 212 labs”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
Center-to-lab ratio: 24:1 (FY26)
p. 8
“And the center-to-lab ratio, which strengthened from 20:1 to 24:1, is a clear testament to the focused execution over the last year to improve network density and drive higher throughput from the infrastructure we have already built”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
Interim dividend: INR1 per share
p. 5
“I'm pleased to share that the Board has also recommended another interim dividend of INR1 per share”
Ameera Shah, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth CAGR — 14% to 15% · next 3 years
stated firmly by Ameera Shah
p. 6
“Over the next 3 years, the vision is to grow at a CAGR of 14% to 15% in revenue.”
Ameera Shah, page 6 of the filed PDF · View the filing
Group EBITDA margin — 27% to 28% · next 3 years
stated as an aspiration by Ameera Shah
p. 6
“the goal of achieving a sustainable group EBITDA margin of 27% to 28% over the next 3 years, supported by profitability across every regional market and bringing core to a 20% plus margin profile”
Ameera Shah, page 6 of the filed PDF · View the filing
Core Diagnostics EBITDA margin — 20%-plus · 3-year commitment
stated firmly by Ameera Shah
p. 5
“We are on our path for our 3-year commitment for a 20%-plus EBITDA at core.”
Ameera Shah, page 5 of the filed PDF · View the filing
Mini hubs network — 100 mini hubs · next 3 years
stated firmly by Ameera Shah
p. 6
“We're also building a network of 100 mini hubs over the next 3 years, which will encompass pathology and basic radiology to service retail and corporate clientele.”
Ameera Shah, page 6 of the filed PDF · View the filing
Collection center network — 1,500 more centers · 3 years
stated firmly by Ameera Shah
p. 6
“We would expand our asset-light collection center network by adding 1,500 more centers, taking the lab-to-center ratio to 1: 35 from the current 1:24, and enhancing center productivity of existing centers by 20% over 3 years.”
Ameera Shah, page 6 of the filed PDF · View the filing
Lab-to-center ratio — closer to 30:1 · next 18 months
stated conditionally by Surendran Chemmenkotil
p. 8
“Over the next 18 months, we expect to strengthen the feeder center network further and move this ratio closer to 30:1 in many markets, depending on cluster maturity, and over a 3-year horizon, we want to take this to 35:1 lab-to-center ratio.”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
EBITDA margin improvement — 125 to 150 bps · coming year
stated firmly by Surendran Chemmenkotil
p. 11
“So we'll definitely be looking at about 125 to 150 bps improvement in the coming year.”
Surendran Chemmenkotil, page 11 of the filed PDF · View the filing
Patient volume growth — 8% to 9% · coming fiscal
stated firmly by Surendran Chemmenkotil
p. 11
“So, about 8% to 9% of patient volume growth is what we are estimating for the coming fiscal for sure, right?”
Surendran Chemmenkotil, page 11 of the filed PDF · View the filing
Price hike — this fiscal
stated conditionally by Surendran Chemmenkotil
p. 10
“Well, at this point of time, we are not looking at a price increase. But as the year progresses, if there is a need for us to do it, we would not hesitate to do so.”
Surendran Chemmenkotil, page 10 of the filed PDF · View the filing
Specialty revenue contribution — around 40% · this year
stated as an aspiration by Surendran Chemmenkotil
p. 11
“I think so.”
Surendran Chemmenkotil, page 11 of the filed PDF · View the filing
TruHealth revenue mix — beyond 25% · next 2 to 3 years
stated as an aspiration by Surendran Chemmenkotil
p. 15
“Well, I mean, this can definitely go beyond 25% as well, I mean, in the next 2 to 3 years period.”
Surendran Chemmenkotil, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Ameera Shah said there is no third-party data but management sees a movement toward bigger, more trusted brands, and guided 14-15% growth as a mix of volume, RPP and price increase.
Answered by Ameera Shah
Asked by Tausif: Whether there is a structural shift from unorganized to organized players and competition from online players.
p. 10
“there is a movement happening, where consumers and doctors are finding more comfort in bigger brands, which have more predictability, and also the specialty market is increasing”
Ameera Shah, page 10 of the filed PDF · View the filing
Ameera Shah explained mini hubs add basic radiology modalities and cost roughly Rs 30-40 lakh, higher than collection centers.
Answered by Ameera Shah
Asked by Sudarshan Agarwal: Nature and capex requirement of mini hubs versus collection centers.
p. 12
“About INR 30 lakh, INR 40 lakh is approximately what we are estimating at this point in time.”
Ameera Shah, page 12 of the filed PDF · View the filing
Sameer Patel confirmed there is an elimination of revenue and margin at consolidation when Core/Specialty processes MHL-generated business.
Answered by Sameer Patel
Asked by Sudarshan Agarwal: Reconciling Core Diagnostics margin with intersegment eliminations.
p. 12
“So, what happens when the business is generated from MHL and the processing happens on the Specialty and the Core, at the consolidation level, there is an elimination of revenue and the margin that will be there.”
Sameer Patel, page 12 of the filed PDF · View the filing
Surendran Chemmenkotil said Tier 3 markets are growing 26-30% versus lower growth in Tier 1/Tier 2.
Answered by Surendran Chemmenkotil
Asked by Surya Patra: Whether Tier 2/3 markets are growing faster than Tier 1.
p. 13
“And Tier 3, we are growing at about 26% to 30% in the last few quarters.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
Ameera Shah said the company remains selective but continues to see M&A opportunities over the next few years.
Answered by Ameera Shah
Asked by Surya Patra: Scope for further inorganic growth/M&A.
p. 13
“But broadly, I think we can continue to see inorganic action for the next few years.”
Ameera Shah, page 13 of the filed PDF · View the filing
Surendran Chemmenkotil attributed it to lab platform consolidation, technology upgrades, barcoding, and a pause in new lab additions.
Answered by Surendran Chemmenkotil
Asked by Kunal Thanvi: What is driving gross margin expansion across diagnostic players.
p. 16
“we have undertaken a lab platform consolidation and upgrades. We are just consolidating some of the vendors and moving into better, higher-efficiency, more productive, technology-enabled, and scalable platforms.”
Surendran Chemmenkotil, page 16 of the filed PDF · View the filing
Ameera Shah said the company targets sustainable 27-28% EBITDA rather than maximizing margins, preferring to reinvest operating leverage gains.
Answered by Ameera Shah
Asked by Kunal Thanvi: Long-term steady-state margin potential for the business.
p. 17
“We believe a sustainable EBITDA of 27% to 28% over the next 3 years makes sense for us.”
Ameera Shah, page 17 of the filed PDF · View the filing
Surendran Chemmenkotil said Mumbai overall grows at 13-14% and it would be difficult to break down by micro-market.
Answered by Surendran Chemmenkotil
Asked by Kaustav Bubna: Growth rate breakdown across different areas of Mumbai.
p. 17
“And in Mumbai also, we are growing at 13%, 14% kind of revenue growth on a year-on-year basis.”
Surendran Chemmenkotil, page 17 of the filed PDF · View the filing
Risks flagged
No price increase taken in Q4 due to GST reasons, meaning price lever remains an opportunity rather than realized growth.
p. 7
“It is also important to note that unlike last year, we did not take a price increase in quarter 4 due to GST reasons.”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
Insurance segment test volumes remain insignificant, indicating an underdeveloped channel.
p. 13
“That's very insignificant at this point in time. We don't have high volumes from the insurance segment as of now.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
Quality of many acquisition targets in the market may not meet the company's standards, limiting inorganic opportunities.
p. 13
“But we generally find that the quality of many of the assets available for acquisition may not meet our standards for what we would like to buy.”
Ameera Shah, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.